GIPR, or Gastric Inhibitory Polypeptide Receptor, mediates GIP-induced secretion of insulin by pancreatic islet beta cells after a meal. GIP is a gastrointestinal peptide hormone of 42 aa that is released from duodenal endocrine K cells after absorption of glucose or fat. Stimulation of the GIPR on pancreatic cells activates adenylyl cyclase and mitogen-activated protein kinase, resulting in increased insulin secretion. Mice with a targeted mutation of GIPR have higher blood glucose levels with impaired initial insulin response after oral glucose load. Analysis of GIPR knockout mice suggest that GIPR defects may contribute to the pathogenesis of diabetes and obesity. Ectopic expression of functional GIPR and its coupling to steroidogenesis has been suggested to be the main cause of food-dependent Cushing's syndrome. Two isoforms of GIPR are produced by alternative splicing. GIPR expression has been reported in human bone, fetal adrenal, and pancreas. Little expression has been identified in normal adult adrenal, but overexpression of GIPR has been observed in the adrenal in food-dependent Cushing's syndrome. GIPR expression has been identified in rat brain, heart, pancreas, and small intestine. ESTs have been isolated from colon libraries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our GIPR Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.